EYWA
Buenos Aires, Argentina· Est.
Sustainable, clinical‑grade psychedelics for next‑generation mental health therapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Sustainable, clinical‑grade psychedelics for next‑generation mental health therapies.
DepressionAnxietyPTSDAddictionMood disorders
Technology Platform
Proprietary, sustainable GMP‑grade synthesis and extraction pipeline delivering high‑purity, reproducible psychedelic compounds for clinical research and therapeutic use.
Opportunities
Scaling sustainable GMP production and advancing BPL-003 to Phase 3 could position Eywa as a key supplier for the growing psychedelic mental‑health market.
Risk Factors
Regulatory uncertainty, clinical trial outcomes, and competition from better‑funded psychedelic firms pose significant execution risks.
Competitive Landscape
Eywa competes with companies like Compass Pathways, MindMed, and ATAI Therapeutics, differentiating itself through its sustainability‑focused manufacturing platform.